PATENT CLAIM ANALYSIS

Application Number: 15873703
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-11
Patent Classification: ["514", "217000"]

Abstract:
Methods of treating a head and neck cancer are disclosed.

Claim (Index 41):
The method of  claim 38 , wherein the anti-cancer agent is chosen from 4-hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), 5-azacytidine, 6-mercaptopurine, 6-thioguanine, actinomycin D, amsacrine, bis-chloroethylnitrosurea, bleomycin, bryostatin-1, busulfan, carboplatin, chlorambucil, cisplatin, cetuximab, colchicine, cyclophosphamide, cytarabine, cytosine arabinoside, dacarbazine, daunorubicin, daunomycin, dactinomycin, deoxycoformycin, diethylstilbestrol (DES), doxorubicin, etoposide (VP-16), epirubicin, esorubicin, gemcitabine, hexamethylmelamine, hydroxyprogesterone, hydroxyurea, idarubicin, ifosfamide, irinotecan, mafosfamide, melphalan, methotrexate (MTX), methylcyclohexylnitrosurea, mithramycin, mitomycin C, mitoxantrone, nitrogen mustards, paclitaxel, pentamethylmelamine, prednisone, procarbazine, tamoxifen, taxol, teniposide, testosterone, trimetrexate, topotecan, vincristine, or vinblastine.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 86.0
- Lexical Diversity: 1.0
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13958502', '15200088', '13826056', '14645578', '13557988']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7761646910257335
- 35 USC 102 Novelty (BERT): 0.6007034307458564
- Combined Prediction Score: 0.7586185649977457
- Mean Citation Score: 387.769794
- Max Citation Score: 580.8186599999998
- Similarity Product: 415.23557846042615

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test